Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial
- PMID: 20980048
- DOI: 10.1016/S0140-6736(10)61230-5
Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial
Abstract
Background: Poliovirus types 1 and 3 co-circulate in poliomyelitis-endemic countries. We aimed to assess the immunogenicity of a novel bivalent types 1 and 3 oral poliovirus vaccine (bOPV).
Methods: We did a randomised, double-blind, controlled trial to assess the superiority of monovalent type 2 OPV (mOPV2), mOPV3, or bOPV over trivalent OPV (tOPV), and the non-inferiority of bivalent vaccine compared with mOPV1 and mOPV3. The study was done at three centres in India between Aug 6, 2008, and Dec 26, 2008. Random allocation was done by permuted blocks of ten. The primary outcome was seroconversion after one monovalent or bivalent vaccine dose compared with a dose of trivalent vaccine at birth. The secondary endpoints were seroconversion after two vaccine doses compared with after two trivalent vaccine doses and cumulative two-dose seroconversion. Parents or guardians and study investigators were masked to treatment allocation. Because of multiple comparisons, we defined p≤0·01 as statistically significant. This trial is registered with Current Controlled Trials, ISRCTN 64725429.
Results: 900 newborn babies were randomly assigned to one of five vaccine groups (about 180 patients per group); of these 70 (8%) discontinued, leaving 830 (92%) for analysis. After the first dose, seroconversion to poliovirus type 1 was 20% for both mOPV1 (33 of 168) and bOPV (32 of 159) compared with 15% for tOPV (25 of 168; p>0·01), to poliovirus type 2 was 21% (35 of 170) for mOPV2 compared with 25% (42 of 168) for tOPV (p>0·01), and to poliovirus type 3 was 12% (20 of 165) for mOPV3 and 7% (11 of 159) for bOPV compared with 4% (7 of 168) for tOPV (mOPV3 vs tOPV p=0·01; bOPV vs tOPV; p>0·01). Cumulative two-dose seroconversion to poliovirus type 1 was 90% (151 of 168) for mOPV1 and 86% (136 of 159) for bOPV compared with 63% (106 of 168) for tOPV (p<0·0001), to poliovirus type 2 was 90% (153 of 170) for mOPV2 compared with 91% (153 of 168) for tOPV (p>0·01), and to poliovirus type 3 was 84% (138 of 165) for mOPV3 and 74% (117 of 159) for bOPV compared with 52% (87 of 168) for tOPV (p<0·0001). The vaccines were well tolerated. 19 serious adverse events occurred, including one death; however, these events were not attributed to the trial interventions.
Interpretation: The findings show the superiority of bOPV compared with tOPV, and the non-inferiority of bOPV compared with mOPV1 and mOPV3.
Funding: GAVI Alliance, World Health Organization, and Panacea Biotec.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Comment in
-
Poliomyelitis eradication: another step forward.Lancet. 2010 Nov 13;376(9753):1624-5. doi: 10.1016/S0140-6736(10)61427-4. Epub 2010 Oct 25. Lancet. 2010. PMID: 20980047 No abstract available.
-
Pakistan: the final frontier for a polio-free world.Lancet. 2011 Jan 15;377(9761):207-8. doi: 10.1016/S0140-6736(11)60046-9. Lancet. 2011. PMID: 21237398 No abstract available.
Similar articles
-
Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.Lancet. 2016 Jul 9;388(10040):158-69. doi: 10.1016/S0140-6736(16)00703-0. Epub 2016 May 19. Lancet. 2016. PMID: 27212429 Clinical Trial.
-
Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.Lancet Infect Dis. 2015 Nov;15(11):1273-82. doi: 10.1016/S1473-3099(15)00219-4. Epub 2015 Aug 26. Lancet Infect Dis. 2015. PMID: 26318714 Clinical Trial.
-
Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.Lancet. 2015 Dec 12;386(10011):2413-21. doi: 10.1016/S0140-6736(15)00237-8. Epub 2015 Sep 18. Lancet. 2015. PMID: 26388534 Clinical Trial.
-
Oral and inactivated poliovirus vaccines in the newborn: a review.Vaccine. 2013 May 17;31(21):2517-24. doi: 10.1016/j.vaccine.2012.06.020. Epub 2012 Jun 20. Vaccine. 2013. PMID: 22728224 Free PMC article. Review.
-
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review.Rev Infect Dis. 1991 Sep-Oct;13(5):926-39. doi: 10.1093/clinids/13.5.926. Rev Infect Dis. 1991. PMID: 1660184 Review.
Cited by
-
Nutritional Status Link with Polioseronegativity Among Children from Poliomyelitis Transmission High-Risk Area of the Democratic Republic of the Congo (DRC).J Multidiscip Healthc. 2024 Mar 19;17:1219-1229. doi: 10.2147/JMDH.S437351. eCollection 2024. J Multidiscip Healthc. 2024. PMID: 38524863 Free PMC article.
-
Prediction Model with Validation for Polioseronegativity in Malnourished Children from Poliomyelitis Transmission High-Risk Area of the Democratic Republic of the Congo (DRC).Pragmat Obs Res. 2023 Dec 21;14:155-165. doi: 10.2147/POR.S437485. eCollection 2023. Pragmat Obs Res. 2023. PMID: 38146546 Free PMC article.
-
Does IPV Boost Intestinal Immunity among Children under Five Years of Age? An Experience from Pakistan.Vaccines (Basel). 2023 Sep 1;11(9):1444. doi: 10.3390/vaccines11091444. Vaccines (Basel). 2023. PMID: 37766121 Free PMC article.
-
Poliovirus type 1 systemic humoral and intestinal mucosal immunity induced by monovalent oral poliovirus vaccine, fractional inactivated poliovirus vaccine, and bivalent oral poliovirus vaccine: A randomized controlled trial.Vaccine. 2023 Sep 22;41(41):6083-6092. doi: 10.1016/j.vaccine.2023.08.055. Epub 2023 Aug 29. Vaccine. 2023. PMID: 37652822 Free PMC article. Clinical Trial.
-
The Fight against Poliovirus Is Not Over.Microorganisms. 2023 May 17;11(5):1323. doi: 10.3390/microorganisms11051323. Microorganisms. 2023. PMID: 37317297 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials